Tanuj Mehra
Senior Partner
Expertise:
Tanuj Mehra brings more than a decade of experience working at the intersection of commercial and R&D with both large pharmaceutical and smaller biopharma clients. He has led numerous global engagements with leading Fortune 500 companies across the healthcare and life sciences sectors, designing and implementing corporate and business unit strategy, operational transformation and technology-driven innovation.
Prior to joining the team, Tanuj held a series of progressive roles at Deloitte, most recently serving as senior manager, based on the West Coast, with earlier stints in New York and Basel (Switzerland). At Deloitte, Tanuj served as a strategic advisor and execution partner to executive cross-functional leadership teams, including c-suites, demonstrating his ability to craft strategies, develop implementation plans and successfully deliver measurable value. As a leader in Deloitte’s Life Sciences Strategy practice, Tanuj had business development responsibility for key strategic client accounts. Among his accomplishments, Tanuj led a multi-year transformation project at a top-five pharmaceutical company, automating processes; reducing costs; and improving outcomes through cognitive automation, machine learning and artificial intelligence (AI). Tanuj also represented Deloitte at the Amazon re:Invent 2019 conference, showcasing a solution for the automation of pharmacovigilance case processing.
Tanuj started his career at Evotope Biosciences, first as a molecular biologist and eventually as a project manager overseeing overall R&D and forging collaborative partnerships with other startups and universities while working to secure funding from angel investors. Tanuj’s scientific writing includes a paper in the Journal of Investigative Dermatology on reducing excessive wound contraction in pathological conditions. He holds an MBA from Duke University, a Master of Science degree in biomedical engineering from Stony Brook University, and a bachelor’s degree in biomedical engineering from the University of Mumbai.
Articles by Tanuj Mehra
Navigating the Frontier: Generative AI Revolutionizing Healthcare and Life Sciences
In the dynamic landscape of healthcare and life sciences, the integration of cutting-edge technologies has become paramount. Among these innovations, Artificial Intelligence (AI) stands out as a transformative force, reshaping everything from drug discovery to patient care. In this white paper, Tanuj Mehra, Jordan Schell, Erion Lipo and Kevin Yin shed light on the pivotal role of AI, particularly Generative AI. At the heart of this transformation lies Generative AI, a technology that simulates human intelligence in machines, encompassing machine learning, natural language processing, and computer vision. This versatile tool has found widespread recognition, catalyzing mainstream adoption and driving innovation across various sectors. The white paper delves into the diverse […]
Account Engagement Excellence: How Advanced Analytics Can Enable Next-Generation Account Segmentation
Account/customer segmentation is a crucial exercise at the beginning of any strategy related to healthcare provider, patient, or payer engagement. Due to the large variety of customers, it is critical to know one’s customers well, from basic information such as demographics, firmographics, and geography, to more nuanced aspects of the customers’ beliefs, attitudes, and the psychology that drives their behaviors. All this information is critical to formulating the right messages and strategies to engage customers most effectively. Account segmentation allows for accounts to be grouped based on their behaviors, capabilities, strengths, and challenges. By grouping accounts, one can better understand similarities and differences to draw implications for account needs and […]
Social Determinants of Health – What Pharma Can Do!
The US Department of Health and Human Services defines Social Determinants of Health (SDoH) as conditions in the places where people live, learn, work, and play that affect a wide range of health risks and outcomes.1 They can be grouped into five major categories: economic stability, education access and quality, healthcare access and quality, neighborhood and built environment, and social and community context. SDoH are considered to be the root causes of health disparities across segments of the population. According to GoInVo, 68% of the impact on health comes from SDoH factors versus other factors such as genetics and medical care.2 Population health – an interdisciplinary, customizable approach that allows […]
Rx-to-OTC Switch Tips: Identifying the Right Timing, Conditions, and Approach for Rx-to-OTC Conversion
Exploring the idea of converting a prescription (Rx) drug to an over-the-counter (OTC) product can be a useful part of life cycle management and loss of exclusivity planning. However, while an Rx-to-OTC switch could provide significant benefits to patients and a potential revenue source for drugs facing loss of exclusivity (LOE), manufacturers considering this strategy must overcome a number of hurdles. This white paper will: Review the current state and examine the potential reasons behind the limited number of recent Rx-to-OTC switches. Outline conditions a product must meet to be a viable contender to switch. Highlight the regulatory requirements for such a switch. Detail considerations for manufacturers exploring this strategy […]
Learning How to Play Dilution Dodgeball
The healthcare industry is reaching new heights in innovation, and as new drugs are founded, owners of biotech companies must decide whether or not they want to independently bring their product to market. Developing and successfully commercializing a biopharma product is no small undertaking. The multi-year journey is fraught with clinical, financial and operational uncertainties that many companies fail to overcome. By time the company reaches commercialization, founders usually see more than 90% reduction in equity overall. What if there was a low-risk alternative to circumvent equity dilution, allowing founders to have the best of both worlds? In today’s market – this option does exist. Download this article to learn how to play “Dilution Dodgeball” as you successfully commercialize your product and […]